VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
STAASTAAR Surgical Company
$29.29$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksSTAAFinancials

STAAR Surgical Company (STAA) Financials

30Y historyFree accessUpdated daily

Despite a 119.6% revenue surge in 2026Q1, the company struggles with structural profitability as evidenced by an operating margin that has fluctuated between -134.8% and 19.5% over the last five quarters.

STAA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMJan'26Dec'24Dec'23Dec'22Dec'21Jan'21Jan'20Dec'18Dec'17Dec'16Jan'16Jan'15Jan'14Dec'12Dec'11Dec'10Jan'10Jan'09Dec'07Dec'06Dec'05Dec'04Jan'04Jan'03Dec'01Dec'00Dec'99Jan'99Jan'98Jan'97
Sales/Revenue290.38M239.44M313.9M322.42M284.39M230.47M163.46M150.19M123.95M90.61M82.43M77.12M74.99M72.22M63.78M62.77M54.96M75.34M74.89M59.36M56.28M51.3M51.69M50.46M48.25M50.24M53.99M59M54.2M42.5M42.2M
Revenue Growth %4.03%-23.72%-2.64%13.37%23.39%41%8.84%21.16%36.8%9.92%6.88%2.85%3.84%13.22%1.62%14.21%-27.06%0.6%26.16%5.47%9.71%-0.74%2.43%4.58%-3.96%-6.94%-8.5%8.86%27.53%0.71%21.61%
Cost of Goods Sold68.44M57.02M74.32M69.76M61.01M51.84M45.1M38.23M32.44M26.33M24.06M24.4M26.16M21.91M19.49M20.4M19.88M33.45M34.79M30.1M29.85M27.52M25.54M22.62M24.1M28.2M22.6M18.7M14.1M6.8M7.9M
COGS % of Revenue-23.81%23.68%21.64%21.45%22.49%27.59%25.46%26.17%29.06%29.19%31.64%34.89%30.33%30.56%32.5%36.18%44.4%46.45%50.7%53.03%53.64%49.42%44.83%49.95%56.14%41.86%31.69%26.01%16%18.72%
Gross Profit221.94M182.42M239.58M252.65M223.38M178.64M118.36M111.95M91.51M64.28M58.37M52.72M48.82M50.31M44.29M42.37M35.08M41.89M40.11M29.27M26.43M23.79M26.14M27.84M24.15M22.03M31.39M40.3M40.1M35.7M34.3M
Gross Margin %76.43%76.19%76.32%78.36%78.55%77.51%72.41%74.54%73.83%70.94%70.81%68.36%65.11%69.67%69.44%67.5%63.82%55.6%53.55%49.3%46.97%46.36%50.58%55.17%50.05%43.86%58.14%68.31%73.99%84%81.28%
Gross Profit Growth %--23.86%-5.17%13.1%25.05%50.92%5.72%22.34%42.36%10.13%10.71%7.99%-2.95%13.59%4.54%20.79%-16.27%4.45%37.04%10.72%11.13%-9.02%-6.09%15.27%9.6%-29.8%-22.12%0.5%12.32%4.08%23.38%
Operating Expenses226.94M228.37M252.19M224.55M179.58M145.3M111.59M100.1M84.92M67.91M71.02M58.06M56.85M49.61M45.51M39.59M37.68M45.62M60.49M43.38M40.03M34.6M36.3M34.36M31.26M32.59M51.57M36.3M33.5M26.4M24.2M
OpEx % of Revenue-95.37%80.34%69.65%63.15%63.04%68.27%66.65%68.51%74.95%86.16%75.28%75.81%68.7%71.35%63.07%68.56%60.55%80.77%73.08%71.13%67.44%70.24%68.1%64.79%64.87%95.52%61.53%61.81%62.12%57.35%
Selling, General & Admin177.31M188.31M198.22M180.15M143.6M111.44M79.67M74.8M62.89M48.8M50.73M43.3M44.36M42.7M39.07M33.72M31.25M39.97M42.78M36.67M33.29M29.02M30.05M29.24M25.79M28.79M43.62M27.8M25.5M19M17.8M
SG&A % of Revenue-78.65%63.15%55.88%50.49%48.35%48.74%49.81%50.73%53.85%61.54%56.14%59.16%59.13%61.25%53.72%56.87%53.05%57.12%61.78%59.14%56.58%58.15%57.95%53.46%57.31%80.81%47.12%47.05%44.71%42.18%
Research & Development38.43M40.05M53.97M44.4M35.98M33.86M31.92M25.3M22.03M19.12M20.29M14.76M12.36M6.71M6.44M5.87M5.72M5.89M7.94M6.71M7.08M5.57M6.25M5.12M4.02M3.8M4.22M4.3M3.6M3.9M4.1M
R&D % of Revenue-16.73%17.19%13.77%12.65%14.69%19.53%16.84%17.77%21.1%24.62%19.14%16.49%9.29%10.1%9.35%10.42%7.82%10.6%11.3%12.58%10.86%12.08%10.15%8.32%7.56%7.81%7.29%6.64%9.18%9.72%
Other Operating Expenses2M0000000715K628K470K0381K486K00700K-238K9.77M0-331K0001.45M03.73M4.2M4.4M3.5M2.3M
Operating Income-5.01M-45.95M-12.61M28.1M43.8M33.34M6.77M11.85M6.59M-3.63M-12.65M-5.34M-8.03M700K-1.22M2.78M-2.6M-3.73M-20.39M-14.12M-13.6M-10.81M-10.16M-6.53M-7.11M-17.79M-20.18M4M6.6M9.3M10.1M
Operating Margin %-1.72%-19.19%-4.02%8.71%15.4%14.47%4.14%7.89%5.32%-4.01%-15.35%-6.92%-10.7%0.97%-1.91%4.43%-4.73%-4.95%-27.22%-23.78%-24.17%-21.07%-19.65%-12.93%-14.74%-35.4%-37.38%6.78%12.18%21.88%23.93%
Operating Income Growth %--264.33%-144.88%-35.85%31.38%392.52%-42.89%79.71%281.63%71.31%-137.12%33.51%-1246.71%157.38%-143.84%206.96%30.22%81.71%-44.39%-3.8%-25.8%-6.44%-55.68%8.27%60.01%11.87%-604.55%-39.39%-29.03%-7.92%42.25%
EBITDA3.6M-37.22M-5.72M33.22M48.31M36.98M9.86M15.55M9.06M-277K-9.76M-2.94M-5.57M2.85M741K5.05M-196K14K-16.75M-11.61M-11.23M-8.34M-7.46M-3.62M-4.01M-14.16M-16.45M8.2M11M12.8M12.4M
EBITDA Margin %1.24%-15.54%-1.82%10.3%16.99%16.05%6.03%10.35%7.31%-0.31%-11.84%-3.81%-7.42%3.95%1.16%8.04%-0.36%0.02%-22.36%-19.56%-19.95%-16.26%-14.44%-7.18%-8.31%-28.19%-30.47%13.9%20.3%30.12%29.38%
EBITDA Growth %106.02%-550.66%-117.22%-31.24%30.64%274.91%-36.57%71.66%3370.4%97.16%-232.53%47.26%-295.26%284.75%-85.32%2676.02%-1500%100.08%-44.23%-3.39%-34.65%-11.72%-106.04%9.63%71.69%13.91%-300.63%-25.45%-14.06%3.23%44.19%
D&A (Non-Cash Add-back)8.6M8.73M6.89M5.12M4.51M3.64M3.1M3.7M2.46M3.35M2.89M2.4M2.46M2.15M1.96M2.27M2.41M3.74M3.64M2.51M2.37M2.47M2.69M2.9M3.1M3.62M3.73M4.2M4.4M3.5M2.3M
EBIT6.19M-45.95M-12.61M28.1M43.8M33.34M6.77M11.85M6.59M-3.63M-12.65M-5.48M-5.34M1.28M-228K3.23M-2.79M-4.43M-20.77M-14.12M-13.6M-10.81M-10.16M-6.53M-7.11M-10.55M-20.18M4M6.6M9.3M10.1M
Net Interest Income4.13M4.59M5.91M6.99M2.45M-38K238K988K165K-112K-112K-78K-103K-111K-232K-491K-853K-1.25M-741K000000000000
Interest Income4.13M4.59M5.91M6.99M2.45M-238K988K165K03K50K51K59K59K32K43K60K160K00000270K000000
Interest Expense0000038K000112K115K128K154K170K291K523K896K1.33M901K000000000000
Other Income/Expense-14.55M-36.32M3.56M5.6M1.75M-2.04M1.5M1.17M44K1.33M211K-268K-618K414K701K-79K-1.08M-741K-1.28M-1.04M95K854K-88K-705K-1.01M2.99M-5.3M-900K-500K2.4M100K
Pretax Income-19.56M-82.26M-9.05M33.7M45.55M31.3M8.27M13.03M6.64M-2.3M-12.44M-5.61M-8.64M1.11M-519K2.7M-3.68M-4.71M-21.67M-15.16M-13.51M-9.96M-10.25M-7.16M-8.12M-18.24M-25.48M3.1M6.1M11.7M10.2M
Pretax Margin %-6.74%-34.36%-2.88%10.45%16.02%13.58%5.06%8.67%5.36%-2.53%-15.1%-7.27%-11.53%1.54%-0.81%4.31%-6.7%-6.25%-28.94%-25.53%-24%-19.41%-19.82%-14.19%-16.84%-36.31%-47.2%5.25%11.25%27.53%24.17%
Income Tax1.47M-1.81M11.16M12.35M5.89M3.79M2.35M-1.02M1.67M-157K-315K928K-253K716K1.24M1.36M432K1.49M1.52M843K1.54M1.24M1.06M1.13M8.96M-3.55M-6.58M900K2M4.3M3.3M
Effective Tax Rate %-7.53%2.21%-123.24%36.65%12.92%12.12%28.47%-7.85%25.17%6.84%2.53%-16.56%2.93%64.27%-239.69%50.15%-11.74%-31.69%-7.03%-5.56%-11.38%-12.44%-10.32%-15.74%-110.28%19.45%25.82%29.03%32.79%36.75%32.35%
Net Income-21.03M-80.45M-20.21M21.35M39.66M27.51M5.91M14.05M4.97M-2.14M-12.13M-6.53M-8.39M398K-1.76M1.35M53K-6.2M-23.2M-16M-15.04M-11.18M-11.33M-8.36M-17.16M-14.83M-18.9M2.2M2.4M7.4M6.9M
Net Margin %-7.24%-33.6%-6.44%6.62%13.95%11.94%3.62%9.35%4.01%-2.36%-14.71%-8.47%-11.19%0.55%-2.76%2.15%0.1%-8.23%-30.97%-26.95%-26.73%-21.78%-21.93%-16.56%-35.56%-29.53%-35.01%3.73%4.43%17.41%16.35%
Net Income Growth %70.41%-298.1%-194.66%-46.18%44.18%365.26%-57.91%182.77%332.26%82.36%-85.66%22.15%-2208.54%122.58%-230.79%2443.4%100.85%73.27%-44.98%-6.35%-34.62%1.39%-35.6%51.29%-15.67%21.53%-959.16%-8.33%-67.57%7.25%-8%
Net Income (Continuing)-21.03M-80.45M-20.21M21.35M39.66M27.51M5.91M14.05M4.97M-2.14M-12.13M-6.53M-8.39M398K-1.76M1.35M-4.11M-6.2M-23.2M-16M-15.04M-11.18M-11.33M-8.36M-17.16M-14.83M-18.9M2.2M4.1M7.4M6.9M
Discontinued Operations0000000000000000000000000000000
Minority Interest000000000000000000000022K204K100K382K203.92K500K900K00
EPS (Diluted)-0.41-1.62-0.410.430.800.500.120.300.11-0.05-0.30-0.17-0.220.01-0.050.040.00-0.19-0.79-0.57-0.60-0.47-0.58-0.47-1.00-0.87-1.230.150.170.530.50
EPS Growth %70.83%-295.12%-195.35%-46.25%60%316.67%-60%172.73%310.73%82.6%-76.47%22.73%-2300%120.58%-221.5%-100.79%75.95%-38.6%5%-27.66%18.97%-23.4%53%-14.94%29.27%-920%-11.76%-67.92%6%-9.09%
EPS (Basic)--1.62-0.410.440.830.520.130.320.11-0.05-0.30-0.17-0.220.01-0.050.040.00-0.19-0.79-0.57-0.60-0.47-0.58-0.47-1.00-0.87-1.230.150.180.570.50
Diluted Shares Outstanding50.9M49.57M49.13M49.43M49.38M49.46M47.95M46.9M45.26M41M40.33M39.26M38.09M38.61M36.25M36.88M34.83M32.5M29.47M28.12M25.23M23.7M19.6M17.7M17.16M17M15.37M14.67M14.12M13.96M13.8M
Basic Shares Outstanding49.91M49.57M49.13M48.52M47.99M47.21M45.6M44.49M45.16M41M40.33M38.43M38.09M36.71M35.26M35.43M34.83M32.5M29.47M28.12M25.23M23.7M19.6M17.7M17.14M17M15.37M14.67M13.33M12.98M13.8M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Geographic revenue concentration risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Volatile Revenue Growth Patterns Observed

As reported in recent financial filings, STAA's revenue trajectory has exhibited extreme volatility, highlighted by a 119.6% surge in 2026Q1 followed by significant contractions in prior periods, suggesting that the company's reliance on elective procedure volumes remains highly sensitive to external macroeconomic and regional demand shifts.

The erratic revenue performance indicates that the company's growth is not yet decoupled from cyclical consumer spending patterns. Investors should monitor whether the recent rebound in 2026Q1 represents a sustainable return to growth or merely a recovery from previous inventory-related channel adjustments.

Structural Gross Margin Resilience Persists

Based on the provided income statement data, STAA maintains a robust gross margin profile, consistently hovering near 75% despite significant top-line fluctuations, which suggests that the proprietary Collamer material provides a durable pricing advantage that remains largely insulated from the company's broader operational and sales-related cost pressures.

This high gross margin is a critical indicator of the company's underlying product value proposition. However, the stability of these margins does not translate to the bottom line, implying that the current challenges are rooted in operating expense management rather than product-level profitability.

Operating Leverage Remains Severely Constrained

According to the company's quarterly income statements, STAA has struggled to achieve positive operating leverage, with SG&A expenses frequently exceeding gross profit, leading to deep operating losses that suggest the current cost structure is misaligned with the company's actualized revenue generation capacity in recent quarters.

The inability to scale operating income alongside gross profit indicates that the company's aggressive investment in sales and marketing is not currently yielding the expected efficiency gains. This warrants further investigation into whether these expenditures are essential for market penetration or represent an inefficient allocation of capital.

Stock-Based Compensation Distorts Earnings Quality

As evidenced by the financial data, STAA's net income is significantly impacted by non-cash charges, including substantial stock-based compensation that reached $8.6 million in 2025Q4, which complicates the assessment of true operational profitability and suggests that reported EPS may not fully reflect the company's underlying cash-generating capability.

The reliance on equity-based incentives during periods of negative net income may dilute shareholder value without providing a clear link to improved operational performance. Analysts should adjust for these items to better understand the company's core earnings power and the true cost of its human capital.

Sustainability of Current Cost Structure

Based on the reported figures, the most significant risk to the investment thesis is the company's persistent cash burn, which appears to be driven by a fixed-cost base that remains elevated despite the recent 23.72% revenue decline, raising concerns about the long-term sustainability of current spending levels.

Short-sellers would likely focus on the disconnect between the company's high-growth narrative and the reality of its negative operating margins. If revenue growth fails to re-accelerate, the company may be forced to choose between aggressive cost-cutting that could impair future growth or further eroding its cash reserves.

STAA — Frequently Asked Questions

Quick answers to the most common questions about buying STAA stock.

What was STAAR Surgical Company's (STAA) revenue in 2025?

For fiscal year 2025, STAAR Surgical Company (STAA) reported total revenue of $239.4M. This represents a 467.4% increase compared to $42.2M in 1996.

Is STAAR Surgical Company (STAA) profitable?

STAAR Surgical Company (STAA) reported a net loss of $80.4M for the fiscal year ending 2025.

What is STAAR Surgical Company's operating profit margin?

STAAR Surgical Company (STAA) reported an operating income of $-45.9M, resulting in an operating profit margin of -19.2%. This margin reflects the operational efficiency of the business before interest and taxes.

What is STAAR Surgical Company's gross profit and gross margin?

STAAR Surgical Company (STAA) generated $182.4M in gross profit for the year, representing a gross profit margin of 76.2%. This demonstrates the company's core pricing power and production efficiency.